Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes.

ABSTRACT: Lymphocytes have always been among the prime targets in gene therapy, even more so since chimeric antigen receptor (CAR) T cells have reached the clinic. However, other gene therapeutic approaches hold great promise as well. The first part of this review provides an overview of current strategies in lymphocyte gene therapy. The second part highlights the importance of precise gene delivery into B and T cells as well as distinct subtypes of lymphocytes. This can be achieved with lentiviral vectors (LVs) pseudotyped with engineered glycoproteins recognizing lymphocyte surface markers as entry receptors. Different strategies for envelope glycoprotein engineering and selection of the targeting ligand are discussed. With a CD8-targeted LV that was recently used to achieve proof of principle for

SUBMITTER: Frank AM 

PROVIDER: S-EPMC6216101 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature